Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: A prospective study of 116 patients

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 385-391

  Brechot J M ^a   Chevret, S ^b   Nataf, J ^a   Le Gall, C ^a   Fretault J ^a   Rochemaure, J ^a   Chastang, Cl ^b  

^a HÔTEL DIEU   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Cyfra 21 1; non small cell lung cancer; prognosis; survival; tumour markers

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031105977     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89010-7     Document Type: Article

References (27)

1. Mountain CF. Lung cancer staging classification. Clin Chest Med. 14:1993;45-53.
2. Mountain CF. A new international staging system for lung cancer. Chest. 89:1986;225-233. (Suppl).
3. Bénichou J, Fabre Ch, Chastang Cl, et al. Facteurs pronostiques du cancer du poumon opéré non à petites cellules: étude à partir d'un essai thérapeutique randomisé Rev Mal Resp. 4:1987;301-309.
4. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 96:1988;440-447.
5. Capewell S, Sudlow MF. Performance and prognosis in patients with lung cancer. Thorax. 45:1990;951-956.
6. Sorensen JB, Badsberg JH, Olsen JH. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients. Cancer Res. 49:1989;5748-5754.
7. Pater JL, Loeb M. Non anatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer. 50:1982;326-331.
8. Kimura Y, Fujii T, Hamamoto K, Miyagawa N, Kataoka M, Lio A. Serum CA 125 level is a good prognostic indicator in lung cancer. Br J Cancer. 62:1990;676-678.
9. Diez M, Torres A, Pollan M, et al. Prognostic significance of serum CA 125 antigen assay in patients with non small cell lung cancer. Cancer. 73:1994;1368-1376.
10. Body J, Sculier JP, Raymakers N, et al. Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer. 65:1990;1552-1556.
11. Niklinski J, Furman M, Laudanski J, Kozlowski M. Evaluation of squamous cell carcinoma antigen (SCC-Ag) in the diagnosis and follow-up of patients with non-small cell lung carcinoma. Neoplasma. 39:1992;279-282.
12. Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H, Michel JB. Serum fragment of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53:1993;61-66.
13. Ebert W, Leichtweis B, Schapöhler B, Muley Th. The new tumor marker Cyfra is superior to SCC antigen and CEA in the primary diagnosis of lung cancer. Tumor Diagnost Ther. 3:1993;91-99.
14. Stieber P, Hasholzner U, Bodenmüller H, et al. A new marker in lung cancer. Cancer. 72:1993;707-713.
15. Rastel D, Ramaioli A, Cornillie F, Thirion B. Cyfra 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicenter evaluation. Eur J Cancer. 30A:1994;601-606.
16. Niklinski J, Furman M, Chyczewska E, et al. Evaluation of Cyfra 21-1 as a new marker for non small cell lung cancer. Eur J Cancer Prev. 3:1994;227-230.
17. Plebani M, Navaglia F, Basso D, et al. Serum Cyfra 21-1 in the assessment of epithelial cancers. J Tumor Marker Oncol. 9:1994;13-17.
18. Sugama Y, Kitamura S, Kawai T, et al. Clinical usefulness of Cyfra assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn Cancer Res. 85:1994;1178-1184.
19. Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Cornillie F, Splinter TAW. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21-1. Br J Cancer. 69:1994;525-528.
20. Rapellino M, Niklinski J, Pecchio F, et al. Cyfra 21-1 as a tumour marker for bronchogenic carcinoma. Eur Respir J. 8:1995;407-410.
21. Takada M, Masuda N, Matsuura E, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by Cyfra 21-1 enzyme immunoassay. Br J Cancer. 71:1995;160-165.
22. Wieskopf B, Demangeat C, Purohit A, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity and prognostic role. Chest. 108:1995;163-169.
23. Last JM. A Dictionary of Epidemiology. 1988;Oxford University Press, New York.
24. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
25. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A. 135:1972;185-206.
26. Cox Dr. Regression models and life tables (with discussion). J R Stat Soc B. 34:1972;187-220.
27. Buccheri G, Ferrigno D. The Tissue Polypeptide Antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods. Chest. 107:1995;471-476.